enzalutamide works in castration-resistant disease<\/strong> where bicalutamide and flutamide have failed. It is also more potent and produces deeper PSA responses but with more cognitive side effects, hypertension and fall risk.<\/p>\nWhy is seizure history a contraindication?<\/h3>\n
Enzalutamide crosses the blood-brain barrier and lowers seizure threshold. In trials, seizure incidence was < 1% but increased in patients with predisposing factors. Avoid enzalutamide in any patient with prior seizure (any type), brain metastases, or concurrent drugs lowering seizure threshold (bupropion, tramadol, clozapine, fluoroquinolones, theophylline). If enzalutamide is essential in such a patient, neurology and oncology specialists must agree on the risk-benefit.<\/p>\n
Will I have to stop ADT (LHRH agonist) when I start Bdenza?<\/h3>\n
No — continue your LHRH agonist (goserelin, leuprorelin, etc.) throughout enzalutamide treatment. The combination of background castration + AR signalling inhibition is essential. Stopping the LHRH agonist allows testosterone to recover, which can defeat enzalutamide's effect.<\/p>\n
Why is fatigue so common on Bdenza?<\/h3>\n
Fatigue is the most common and clinically significant side effect — affecting around 35% of patients in trials. The cause is multifactorial: profound androgen deprivation, possible direct CNS effects, anaemia. Manage with structured exercise (counterintuitively effective), good sleep hygiene, screening and treatment of anaemia, and consideration of dose reduction (160 → 120 mg\/day) if intolerable.<\/p>\n
What is PRES and how do I recognise it?<\/h3>\n
Posterior reversible encephalopathy syndrome (PRES) is a rare but documented enzalutamide complication characterised by severe headache, confusion, visual changes (cortical blindness), seizures and altered consciousness<\/strong>. Stop enzalutamide immediately and seek same-day medical review for any of these symptoms. Most cases resolve with drug discontinuation but timely recognition prevents permanent neurological injury.<\/p>\nAre there many drug interactions I need to worry about?<\/h3>\n
Yes — enzalutamide is a strong CYP3A4 inducer<\/strong> and lowers blood levels of many co-prescribed drugs. The most clinically important: warfarine<\/strong> (switch to a DOAC or check INR weekly), direct oral anticoagulants<\/strong> (specialist review), some statins, some antihypertensives, opioids, some antiepileptics. Tell every doctor you are on enzalutamide.<\/p>\nCan I drive on Bdenza?<\/h3>\n
Caution — fatigue, dizziness and (rarely) seizures may impair driving. Most patients adapt and drive safely after the first few weeks. Avoid driving or operating machinery if you experience significant fatigue, dizziness, or any cognitive symptoms.<\/p>\n
Bdenza vs abiraterone — which is better?<\/h3>\n
Both are second-line options after first-generation anti-androgen failure. Head-to-head data is limited; choice depends on side-effect preference and comorbidities. Enzalutamide:<\/strong> more fatigue, cognitive effects, hypertension, fall risk; no steroid co-prescription needed. Abiraterone:<\/strong> requires concurrent prednisone 5 mg twice daily; more hypertension and fluid retention; may worsen diabetes control. Discuss with your oncologist.<\/p>","protected":false},"excerpt":{"rendered":"\u2705 Slows cancer progression
\n\u2705 Reduces tumor growth
\n\u2705 Improves survival outcomes
\n\u2705 Supports prostate treatment
\n\u2705 Enhances quality of life<\/p>\n
Bdenza<\/strong> bevat Enzalutamide<\/strong> 40 mg.<\/p>","protected":false},"featured_media":67947,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3595],"product_tag":[5422,5423],"class_list":{"0":"post-67946","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_tag-bdenza","8":"product_tag-enzalutamide","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product\/67946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/comments?post=67946"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media\/67947"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media?parent=67946"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_brand?post=67946"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_cat?post=67946"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_tag?post=67946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}